Patel Engg has won a Rs195.21 crore order for rehabilitation of sewerage lines spread across different stretches across the suburban areas in Mumbai
Construction company Patel Engineering has won two urban infrastructure projects amounting to Rs377.04 crore from the Municipal Corporation of Greater Mumbai.
"The company has won a Rs195.21 crore order for rehabilitation of sewerage lines spread across different stretches across the suburban areas in Mumbai," the company said in a statement.
It added that the other Rs181.83 crore project pertains to construction of tunnels from Powai to Veravali and Powai to Ghatkopar high-level reservoir and from Ghatkopar high-level reservoir to Ghatkopar low-level reservoir. The project also involves construction of shafts and allied works.
Currently, Patel Engineering is also executing a Rs363.05 crore road project for the Pune Municipal Corporation (PMC). This project stretches from Shivane to Mhatrae Bridge (Phase-1) and Sangamwadi to Kharadi (Phase-3) in Pune, it added.
In the late afternoon, Patel Engg was trading at around Rs105 per share on the Bombay Stock Exchange, 4.09% down from the previous close.
This is the sixth multiple ROC solution win for Subex in the Middle East
Subex Ltd has been selected to provide its industry leading revenue operations centre (ROC) fraud management and revenue assurance solutions to the leading Middle Eastern mobile operator.
This is the sixth multiple ROC solution win for Subex in the Middle East. The wide range of Subex references in the region as well as Subex's expertise in the fraud management and revenue assurance domain, helped secure the contract.
ROC Fraud Management is Subex's award-winning solution that helps wireless and wireline operators eliminate known frauds, uncover new fraud patterns, minimise fraud run time, augment internal controls and support continuous fraud management process improvement.
ROC revenue assurance is designed not only to detect potential revenue loss, but also to assist an operator with its investigation, diagnosis and recovery of these revenues. It provides unprecedented automated correction capabilities to improve bottom-line results and provide a quick return-on-investment.
In the late afternoon, Subex was trading at around Rs28 per share on the Bombay Stock Exchange, 2.69% down from the previous close.
On 30th November, Ranbaxy had launched Atorvastatin, a generic version of Lipitor in the US market
Gurgaon-based Ranbaxy Laboratories Ltd has launched Atorvastatin Basics, a generic version of the cholesterol lowering drug Sortis in the German market.
Atorvastatin Basics is launched in the strength of 10mg, 20mg, 40mg and 80mg.
Ranbaxy had obtained, pursuant to a settlement agreement with Pfizer, the rights to an early entry of Atorvastatin in the German market. Pfizer's patent for Sortis expires in Germany on 7th May. Daiichi Sankyo Deutschland GmbH will assist in the launch of Atorvastatin Basics. Daiichi Sankyo has a substantial reach amongst cardiologists and physicians in the German market.
Apart from Germany, Daiichi Sankyo and Ranbaxy are working on synergies in other countries, such as India, Romania, Italy and Mexico, among others.
Earlier on 30th November, Ranbaxy had launched Atorvastatin, a generic version of Lipitor in the US market with 180 days of marketing exclusivity, as it was a first-to-file (FTF) applicant on the product. Recently, Ranbaxy also introduced generic Atorvastatin in Australia with three months exclusivity.
In the late afternoon, Ranbaxy was trading at around Rs411 per share on the Bombay Stock Exchange, 1.57% down from the previous close.